Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, positioning ECO Synthesis as an enzymatic manufacturing platform for siRNA as pipelines broaden and scale

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidanceThree presentations at upcoming TIDES USA

Guidance holds steady: Management kept its 2026 revenue target at $72–$76 million, expecting stronger results in the second half. Scaling ambitions: A 0.5 kilogram ECO Synthesis siRNA production scale is planned by year-end, with ongoing process optimization

As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo Ventures and Opaleye Management. Codexis created a ...

As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry,

Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per share (EPS) of $-0.16. Investors in Codexis are eagerly ...

Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of ...

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ...

AI gets playful: OpenAI launched Codex Pets, animated companions that display coding task updates and allow lightweight interaction with its Codex tool. Biotech targets scale: Codexis reaffirmed 2026 revenue guidance and revealed new stereochemistry ...